ABPI
Knobias Clip Report (9-6-2007)
Thursday, September 6th, 2007Submitted from Knobias ClipReport
Interim analysis of a 16-week Fast-Tracked Phase 3 blinded clinical trial of Accentia Biopharmaceuticals Inc.’s (ABPI) SinuNase(TM) (intranasal amphotericin B 0.01% suspension) for the treatment of refractory chronic sinusitis has been completed. The study has shown improvement in polyposis in about 50% of patients and improvement in sinus inflammation in approximately 50% […]
